Hematologic Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Kite, Pfizer to Assess Yescarta-Utomilumab Combination in Lymphoma - Genetic Engineering & Biotechnology News



Kite, Pfizer to Assess Yescarta-Utomilumab Combination in Lymphoma 
Genetic Engineering & Biotechnology News
... Kite worldwide head of research and development and CMO. ?We are pleased to collaborate with Pfizer on this study with utomilumab, which adds to the growing number of combination approaches we are exploring with Yescarta for patients living with ...
Clinical Collab to Evaluate Yescarta and Utomilumab in Large B-Cell Lymphoma Drug Discovery & Development

all 2 news articles » 


Oldest Patients Underrepresented in Hematologic Cancer Trials - Cancer Network



Oldest Patients Underrepresented in Hematologic Cancer Trials 
Cancer Network
?Until now, there has been very little information about the enrollment of adults with hematologic cancers. Based on our findings, the occurrence of cancer is much higher in adults over 75 years of age compared with the proportion of patients in this ...

 


Dr. Lim Appointed Cancer Institute's Medical Director of Hematology - Hudson Valley News Network



Hudson Valley News Network
 
Dr. Lim Appointed Cancer Institute's Medical Director of Hematology 
Hudson Valley News Network
Prior to joining Westchester Medical Center, Dr. Lim most recently served as Director of Hematology at Rhode Island Hospital and Professor of Medicine at Brown University's Warren Alpert Medical School. He has also held appointments in Pittsburgh ...

 


Preventing, Treating Relapse After ASCT in Hematologic Malignancy Patients - Cancer Network



Cancer Network
 
Preventing, Treating Relapse After ASCT in Hematologic Malignancy Patients 
Cancer Network
In this video, Robert J. Soiffer, MD, of the Dana-Farber Cancer Institute in Boston, highlights research into the use of post-transplant therapies to prevent or treat disease recurrence following allogeneic stem cell transplantation (ASCT). Soiffer ...

 


Burden of CMV Infection in HSCT Patients - OncLive



OncLive
 
Burden of CMV Infection in HSCT Patients 
OncLive
<iframe width="560" height="315" src="https://www.youtube.com/embed/VmUXGP7xszg?rel=0&amp;autoplay=1&amp;fs=0" frameborder="0" allow="autoplay; encrypted-media" allowfullscreen></iframe> Transcript: Robert J. Soiffer, MD: I'm Robert Soiffer, from ...

 


Hematologic Cancer Advisor - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Hematologic Cancer Advisor 
Cancer Therapy Advisor
Inherited TP53 variants may be crucial for acute lymphoblastic leukemia (ALL) leukemogenesis and response to treatment, according to a study published in the Journal of Clinical Oncology.1. Li-Fraumeni syndrome, which involves an inherited loss of TP53 ...

and more » 


Introducing 'Current Treatment Algorithms' - BMC Blogs Network (blog)



BMC Blogs Network (blog)
 
Introducing 'Current Treatment Algorithms' 
BMC Blogs Network (blog)
Unlike some traditional practice guidelines and pathways which often provide a list of possible options for treatment, Current Treatment Algorithms will provide highly specific recommendations for the management of a hematologic malignancy, which have ...

 


Brain Cancer Study Opens at Overlook Medical Center - TAPinto.net



Brain Cancer Study Opens at Overlook Medical Center 
TAPinto.net
Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types, including lung, brain, cervical, ovarian tumors and hematologic (blood) cancers. Earlier clinical trials have shown that VAL-083 is comparable ...

and more » 


FDA Cites Lack of Data About Blood Cancer Medications in Older People - Lymphoma News Today



Lymphoma News Today
 
FDA Cites Lack of Data About Blood Cancer Medications in Older People 
Lymphoma News Today
Older patients are underrepresented in clinical trials of treatments for lymphoma and other blood cancers, despite being the largest patient group affected, researchers from the U.S. Food and Drug Administration (FDA) found. The FDA's findings indicate ...

 


Brain Cancer Study Opens at Overlook Medical Center - One of Four Sites in Country - TAPinto.net



TAPinto.net
 
Brain Cancer Study Opens at Overlook Medical Center - One of Four Sites in Country 
TAPinto.net
Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types, including lung, brain, cervical, ovarian tumors and hematologic (blood) cancers. Earlier clinical trials have shown that VAL-083 is comparable ...

and more »